|
Published by: NeuroInsights, LLC
Published: Apr. 23, 2012 - 120 Pages
Table of Contents- 1 Neurodiagnostic Markets
- Sector Overview
- Neurodiagnostics Industry Taxonomy
- FDA Approval and Reimbursement of Diagnostics
- Market Opportunities in Neurology and Psychiatry
- Number of People Impacted by Neurological and Psychiatric Disorders, WW and US
- Neurology Markets and Emerging Diagnostics
- Diagnostic Tests for Alzheimer‘s Disease on the Horizon
- Pathogenic Biomarkers
- Sentinel Pattern Detection
- Imaging
- Software and Cognitive Testing
- Government Funds Support Development of TBI Diagnostic
- Diagnostic for Autism and Developmental Disorders Supports Early Intervention
- Psychiatry Markets and Emerging Diagnostics
- Genetic Tests
- Biomarker Tests
- Imaging
- 2 Neuroimaging
- Computed Tomography (CT)
- Magnetic Resonance Imaging (MRI)
- Nuclear Medicine Imaging (PET, SPECT)
- Electro-encephalography (EEG)
- Neurofeedback and Brain Computer Interfaces
- Magneto-encephalography (MEG)
- 3 In Vitro Diagnostics
- In Vitro Diagnostics Regulatory Landscape
- Genetic Testing and Pharmacogenomics
- Protein Biomarker Assays
- Pattern Recognition in Diagnostics
- 4 Neuroinformatics
- Databases
- Mind Research Network for Neurodiagnostic Discovery
- Neuroinformatics Data Storage
- Paul Allen Brain Atlas Project
- Diagnostic Software
- 5 Investing in Neurodiagnostics
- Venture Capital Investment Trends
- Neurodiagnostic Venture Financings, Companies and Investors 2005-2009
- Public Investment Activity and IPOs
- Diagnostic Initial Public Offerings (IPOs), 2004 - 2009
- Public Neurodiagnostic Related Companies, Stock Performance and Fundamentals
- Merger and Acquisition Activity
- 6 Company Profiles
- Neurodiagnostic Companies: Private
- Neurodiagnostic Companies: Public
- 7 Index
AbstractFully updated third annual industry insider report detailing markets and emerging diagnostics in neurology and psychiatry.
Nearly 2 billion people worldwide and 100 million people in the US are affected by a brain or nervous system disorder including addiction, Alzheimer’s, depression, anxiety, schizophrenia, attention disorders, epilepsy, Parkinson’s disease, sensory disorders, and sleep disorders. Diagnosis of these disorders is rapidly changing as new tools are developed for more objective and personalized assessment and treatment.
In addition to the massive unmet markets, long term growth in neurodiagnostics is being driven by 1) technology advances and equipment upgrades in neuroimaging, 2) new biomarkers and imaging protocols for early diagnosis and disease monitoring, and 3) increased use of imaging and informatics in drug and device development.
Get full details about this report >>
|
